Evaluation of Ablation Index and VISITAG™ (ABI-173)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 340 participants.
Also called NCT03062046
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 340 participants
- Sponsor
- Registry
-
NCT03062046
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Belgium, Denmark, France, Ireland, Italy, Netherlands, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03062046. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-27 (actual); primary completion 2019-03-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Ablation Index and VISITAG™ (ABI-173)
- Acronym
- VISTAX
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Device)
- RF ablation
- Lead sponsor
- Biosense Webster, Inc.
Record details
- Record id
cardio:ct-nct03062046- Content hash
0ee4533e35d6aff1369b025a2b5d93bbaaf9dd24a7e5aabc37aadd2026c87477